Analysts expect that Theravance Biopharma Inc (NASDAQ:TBPH) will post ($1.15) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Theravance Biopharma’s earnings, with the highest EPS estimate coming in at ($1.14) and the lowest estimate coming in at ($1.16). Theravance Biopharma reported earnings per share of ($1.36) during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.4%. The firm is scheduled to report its next quarterly earnings results on Monday, February 26th.
On average, analysts expect that Theravance Biopharma will report full-year earnings of ($4.84) per share for the current fiscal year, with EPS estimates ranging from ($5.01) to ($4.49). For the next financial year, analysts expect that the company will post earnings of ($4.44) per share, with EPS estimates ranging from ($4.75) to ($4.17). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Theravance Biopharma.
TBPH has been the subject of several recent analyst reports. ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Cantor Fitzgerald restated a “buy” rating and set a $55.00 target price on shares of Theravance Biopharma in a research report on Tuesday, November 7th. Needham & Company LLC reaffirmed a “buy” rating on shares of Theravance Biopharma in a research note on Tuesday, December 5th. Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Finally, Robert W. Baird reaffirmed a “sell” rating and set a $22.00 price target on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Theravance Biopharma has a consensus rating of “Hold” and a consensus target price of $41.86.
Shares of Theravance Biopharma (TBPH) traded down $0.13 during trading hours on Thursday, hitting $27.94. The company’s stock had a trading volume of 153,800 shares, compared to its average volume of 143,050. Theravance Biopharma has a fifty-two week low of $23.15 and a fifty-two week high of $43.44. The stock has a market capitalization of $1,510.00, a price-to-earnings ratio of -5.41 and a beta of 2.35. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21.
TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate Theravance Biopharma Inc (TBPH) to Post -$1.15 Earnings Per Share” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/04/zacks-brokerages-anticipate-theravance-biopharma-inc-tbph-to-post-1-15-earnings-per-share.html.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.